3 Upcoming Urothelial Cancer Conferences

August 12, 2021

At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

Updated SITC Immunotherapy Guidelines for Urothelial Cancer

August 03, 2021

The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).

Integrating Advanced Practice Providers into Oncology Settings for Managing Urothelial Cancer

July 06, 2021

According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.